PVTX 321
Alternative Names: PVTX-321Latest Information Update: 19 Jun 2024
At a glance
- Originator Proteovant Therapeutics
- Class Antineoplastics
- Mechanism of Action Estrogen receptor degraders; Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer
Most Recent Events
- 05 Apr 2024 Pharmacokinetics, Pharmacodynamics and adverse events data from a preclincial trial in Breast cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 14 Aug 2023 Proteovant Therapeutics has been acquired by SK biopharmaceuticals
- 14 Mar 2023 Preclinical trials in Breast cancer in USA (unspecified route) before March 2023